Specifying a Second-Site GMP Drug Substance Manufacturing Campaign for a Systemic AAV Gene Therapy: A Request-for-Proposal Framework for Technology Transfer and Process Performance Qualification

Qualifying a second drug substance site for a licensed gene therapy is among the most expensive and schedule-sensitive purchases a biologics sponsor makes, and an ambiguous request for proposal (RFP) multiplies both cost and risk. This article specifies an RFP for a contract development and manufacturing organization (CDMO) to receive the licensed suspension HEK293 triple-transfection process for a hypothetical systemic AAV gene therapy, run one non-GMP engineering batch and three consecutive GMP conformance lots at 2,000 L, validate transferred analytical methods, demonstrate comparability to the licensed process, and initiate stability studies. Technical parameters are given as illustrative starting limits subject to the licensed specification. The RFP sets a 21-month schedule with dependencies, an indicative budget of USD 24.0 to 33.5 million with an itemized structure, mandatory qualifications and a weighted scoring model, and regulatory obligations under 21 C.F.R. 601.12, ICH Q5E, and FDA gene therapy guidance. Recommendations address risk sharing for batch failure, ownership of process improvements, and confidentiality.Keywords: request for proposal; AAV; technology transfer; process performance qualification; comparability; CDMO; 21 C.F.R. 601.12

Authors

Institutions

Publication Details

Journal
Zenodo (CERN European Organization for Nuclear Research)
Published
2026-11-21
DOI
https://doi.org/10.5281/zenodo.24425226
Primary Topic
Virus-based gene therapy research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Specifying a Second-Site GMP Drug Substance Manufacturing Campaign for a Systemic AAV Gene Therapy: A Request-for-Proposal Framework for Technology Transfer and Process Performance Qualification

Kishan Rajput, Peivand Pirouzi, Pruthvirajsinh Sindha, Sukhpreet Singh Maan et al.
Zenodo (CERN European Organization for Nuclear Research)
Virus-based gene therapy research
article

Specifying a Second-Site GMP Drug Substance Manufacturing Campaign for a Systemic AAV Gene Therapy: A Request-for-Proposal Framework for Technology Transfer and Process Performance Qualification

Kishan Rajput, Peivand Pirouzi, Pruthvirajsinh Sindha, Sukhpreet Singh Maan, Vraj Modi
article en

Abstract

Qualifying a second drug substance site for a licensed gene therapy is among the most expensive and schedule-sensitive purchases a biologics sponsor makes, and an ambiguous request for proposal (RFP) multiplies both cost and risk. This article specifies an RFP for a contract development and manufacturing organization (CDMO) to receive the licensed suspension HEK293 triple-transfection process for a hypothetical systemic AAV gene therapy, run one non-GMP engineering batch and three consecutive GMP conformance lots at 2,000 L, validate transferred analytical methods, demonstrate comparability to the licensed process, and initiate stability studies. Technical parameters are given as illustrative starting limits subject to the licensed specification. The RFP sets a 21-month schedule with dependencies, an indicative budget of USD 24.0 to 33.5 million with an itemized structure, mandatory qualifications and a weighted scoring model, and regulatory obligations under 21 C.F.R. 601.12, ICH Q5E, and FDA gene therapy guidance. Recommendations address risk sharing for batch failure, ownership of process improvements, and confidentiality.Keywords: request for proposal; AAV; technology transfer; process performance qualification; comparability; CDMO; 21 C.F.R. 601.12

Zenodo (CERN European Organization for Nuclear Research)
Northeastern University (US)
Virus-based gene therapy research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon
Specifying a Second-Site GMP Drug Substance Manufacturing Campaign for a Systemic AAV Gene Therapy: A Request-for-Proposal Framework for Technology Transfer and Process Performance Qualification — Kishan Rajput, Peivand Pirouzi, et al. · Zenodo (CERN European Organization for Nuclear Research) (2026) | TGRS Research Map | TGRS